In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $3.0 in the prior trading day, Taysha Gene Therapies Inc (NASDAQ: TSHA) closed at $2.92, down -2.67%. In other words, the price has decreased by -$2.67 from its previous closing price. On the day, 1.84 million shares were traded. TSHA stock price reached its highest trading level at $3.0882 during the session, while it also had its lowest trading level at $2.905.
Ratios:
Our goal is to gain a better understanding of TSHA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on July 11, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On June 27, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $5. On April 09, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $9.Piper Sandler initiated its Overweight rating on April 09, 2024, with a $9 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 21 ’25 when Nagendran Sukumar sold 57,054 shares for $2.85 per share. The transaction valued at 162,604 led to the insider holds 1,165,289 shares of the business.
Alam Kamran sold 54,491 shares of TSHA for $155,299 on Aug 21 ’25. The CHIEF FINANCIAL OFFICER now owns 1,187,603 shares after completing the transaction at $2.85 per share. On Aug 21 ’25, another insider, Kamran Alam, who serves as the Officer of the company, bought 54,491 shares for $2.87 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 796561472 and an Enterprise Value of 565387648. For the stock, the TTM Price-to-Sale (P/S) ratio is 98.34 while its Price-to-Book (P/B) ratio in mrq is 3.20. Its current Enterprise Value per Revenue stands at 69.818 whereas that against EBITDA is -6.424.
Stock Price History:
The Beta on a monthly basis for TSHA is 0.96, which has changed by 0.36448598 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $3.31, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 10.69%, while the 200-Day Moving Average is calculated to be 37.65%.
Shares Statistics:
The stock has traded on average 3.51M shares per day over the past 3-months and 3619690 shares per day over the last 10 days, according to various share statistics. A total of 272.73M shares are outstanding, with a floating share count of 220.04M. Insiders hold about 19.34% of the company’s shares, while institutions hold 87.00% stake in the company. Shares short for TSHA as of 1753920000 were 38208254 with a Short Ratio of 10.87, compared to 1751241600 on 39852359. Therefore, it implies a Short% of Shares Outstanding of 38208254 and a Short% of Float of 16.409999.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate the current performance of Taysha Gene Therapies Inc (TSHA) in the stock market.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.25 and -$0.4 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.42, with 5.0 analysts recommending between -$0.26 and -$0.58.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $4.3M, resulting in an average revenue estimate of $7.61M. In the same quarter a year ago, actual revenue was $8.33M
